Skip to main content

ARDS, Human

1
Pipeline Programs
7
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

BioCardia
BioCardiaCA - Sunnyvale
1 program
1
intravenous delivery of allogeneic bone marrow-derived MSCsPhase 11 trial
Active Trials
NCT05491681Withdrawn0Est. Jan 2026
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
EIT-guided PEEPN/A1 trial
PEEP adjustmentN/A1 trial
Active Trials
NCT05307913Completed676Est. May 2025
NCT05442073Completed18Est. Jun 2022
Philips
PhilipsNetherlands - Amsterdam
1 program
Activation of AdvisoryN/A1 trial
Active Trials
NCT04274296Completed472Est. Jan 2023
Baxter
BaxterCosta Rica - Cartago
1 program
Extracorporeal carbon dioxide removalN/A
Baxter International
1 program
Extracorporeal carbon dioxide removalN/A1 trial
Active Trials
NCT06321497Recruiting15Est. Feb 2028
Longeveron
LongeveronMIAMI, FL
1 program
Longeveron Mesenchymal Stem CellsPHASE_11 trial
Active Trials
NCT04629105Unknown70Est. Jul 2025
Direct Biologics
Direct BiologicsTX - Austin
1 program
Bone Marrow Mesenchymal Stem Cell Derived Extracellular VesiclesPHASE_1_21 trial
Active Trials
NCT05127122Withdrawn0Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Direct BiologicsBone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
BioCardiaintravenous delivery of allogeneic bone marrow-derived MSCs
LongeveronLongeveron Mesenchymal Stem Cells
Baxter InternationalExtracorporeal carbon dioxide removal
UNION therapeuticsEIT-guided PEEP
UNION therapeuticsPEEP adjustment
PhilipsActivation of Advisory

Clinical Trials (7)

Total enrollment: 1,251 patients across 7 trials

NCT05127122Direct BiologicsBone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

Start: Dec 2024Est. completion: Dec 20240
Phase 1/2Withdrawn
NCT05491681BioCardiaintravenous delivery of allogeneic bone marrow-derived MSCs

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

Start: Jan 2026Est. completion: Jan 20260
Phase 1Withdrawn
NCT04629105LongeveronLongeveron Mesenchymal Stem Cells

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Start: Jul 2020Est. completion: Jul 202570 patients
Phase 1Unknown
NCT06321497Baxter InternationalExtracorporeal carbon dioxide removal

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

Start: Feb 2024Est. completion: Feb 202815 patients
N/ARecruiting
NCT05307913UNION therapeuticsEIT-guided PEEP

PET - PEEP by EIT for Acute Respiratory Distress Syndrome Trial

Start: Apr 2022Est. completion: May 2025676 patients
N/ACompleted
NCT05442073UNION therapeuticsPEEP adjustment

Effect of Initial Empirical PEEP Setting on the Esophageal Pressure-guided PEEP Titration in ARDS

Start: Mar 2022Est. completion: Jun 202218 patients
N/ACompleted
NCT04274296PhilipsActivation of Advisory

Advisory Lead ARDS Respirator Management

Start: Sep 2020Est. completion: Jan 2023472 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,251 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.